Chiesi, the international research-focused biopharmaceutical and healthcare group, has announced that its phase III clinical safety trial for the development of an innovative carbon minimal inhaler platform is underway.1 The carbon minimal inhaler will replace the current hydrofluorocarbon propellant (HFC 134a) .
As part of our Mission Possible campaign, edie delivers this member-exclusive weekly round-up of five of the best sustainable business success stories of the week. In this week's edition, a boost for off-road electric trucks in Africa, and much more.
Chiesi Global Rare Diseases Presents Long-Term Data On Treatment With Velmanase Alfa In Alpha-Mannosidosis And Announces Additional Presentations At T... menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.